On the afternoon of May 19, the highly anticipated China Glaucoma Innovative Entrepreneurs Forum was grandly held in Beijing. Nthoptic was invited to attend the roundtable discussion. This wonderful conference was hosted by Professor Wang Ningli, Professor of Capital Medical University Affiliated Beijing Tongren Hospital, and Professor Zhai Jia, Professor of Wenzhou Medical University Affiliated Yishiguang Ophthalmic Hospital. At the same time, it brought together many experts in ophthalmology, including Professor Lu Yan from Beijing Century Clinic and Hospital, Professor Qiao Chunyan from Beijing Tongren Hospital, Professor Zhao Ping from Shenyang Aier Ophthalmic Hospital, Professor Liang Yuan from Wenzhou Medical University, and Professor Yu Lei from China Academy of Chinese Medical Sciences as discussants. 

      As the Chief Medical Officer of Nthoptic, Mr. Tang Fu delivered an important speech on the domestic glaucoma treatment device market at the forum. This was also the first time for him to presentNthoptic's viewpoints and achievements at an academic conference. In his speech, he conducted an in-depth analysis of the glaucoma drainage device market and mentioned some major companies occupying the industry market share, including aurolab、Johnson & Johnson Vision、Allergan、abbvie、RHEONMEDICAL、NOVARTIS、GLAUKOSTRANSFORMINGVISION、AaI、nCNOVAEYEMEDICAL、SSanten、IVANTIS、NEWWORLDMEDICAL、iSTARMEDICAL.

      In addition, Mr. Tang Fu, Chief Medical Officer of Nthoptic, also shared his insights into the future glaucoma market. According to his prediction, the North American minimally invasive glaucoma surgery market will reach US$375.966 million by 2029. He also listed some MIGS and other glaucoma treatment devices and equipment that have been marketed or are under registration in China, such as Alcon Ex-press, New World Ahamd valve, Ellex iTrack Canaplasty ABiC, Allergan Xen, New World KDB: Kahook dual blade, Tianjin Youshi Usights, UCP: ultrasound cycloplasty, Kanghong CLASS Laser, Trabectome stopped, etc.

      During his speech, Mr. Tang Fu also elaborated on the promotion path for glaucoma treatment devices to enter the domestic market, including clinical trials, NMPA registration, surgical project application, surgical price and consumable charge code application, consumable provincial bidding, medical insurance procurement, hospital admission license, surgeons, general agents, regional agents and sales representatives. He also mentioned some obstacles in the domestic promotion process, such as charge codes, out-of-pocket fees, prices, consumable ratios, indications (angle opening), surgical success rates and patient expectations.

      This forum provided a platform for industry experts to deeply discuss the current status and future trends in the field of glaucoma treatment. The speech of Nthoptic's Chief Medical Officer Mr. Tang Fu not only demonstrated the company's research and innovation achievements in this field to the participants, but also brought new thinking and inspiration to the industry. Meanwhile, it pointed out the direction forNthoptic's future development and innovation in this area.

Scan the code to follow and know more